Skip to main content
Fig. 2 | Journal of Experimental & Clinical Cancer Research

Fig. 2

From: YTHDC1 is downregulated by the YY1/HDAC2 complex and controls the sensitivity of ccRCC to sunitinib by targeting the ANXA1-MAPK pathway

Fig. 2

Knockdown of YTHDC1 promotes the progression of ccRCC in vivoA-E, 786-O cells were transfected with indicated shRNAs for 72 h. After puromycin selection, cells were subcutaneously injected into the nude mice. The tumor image was shown in panel A, the tumor mass was shown in panel B, the tumor growth curve was shown in panel C. The excised tumors were subjected to IHC staining of YTHDC1 (D) or Ki-67 (E). Data presents as mean ± SD with six replicates. ***, P < 0.001. F-J, A498 cells were transfected with indicated shRNAs for 72 h. After puromycin selection, cells were subcutaneously injected into the nude mice. The tumor image was shown in panel F, the tumor mass was shown in panel G, the tumor growth curve was shown in panel H. The excised tumors were subjected to IHC staining of YTHDC1 (I) or Ki-67 (J). Data presents as mean ± SD with four replicates. **, P < 0.01; ***, P < 0.001

Back to article page